Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer

NCT06319313 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

534

Enrollment

INDUSTRY

Sponsor class

Conditions

Squamous Cell Non-small Cell Lung Cancer

Interventions

DRUG: JMT101
DRUG: docetaxel
DRUG: HB1801

Sponsor

Shanghai JMT-Bio Inc.